Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Ups Oncology Sales Force, Reorganizes It into Blood, Solid Cancer Groups
June 27, 2017
- Unauthorized Additive Used for Yamamoto Chemical’s Zonisamide
June 27, 2017
- Sumitomo Dainippon’s Napabucasin Stumbles on PIII Gastric Cancer Study
June 27, 2017
- Fujifilm, CanBas Pair Up for Joint Research on Peptide-Based Cancer Immunotherapies
June 27, 2017
- Daiichi Sankyo Confident of Achieving US$1 Billion Sales for Edoxaban
June 26, 2017
- FDA Snubs Takeda/Lundbeck’s Reattempt for Trintellix Label Expansion
June 26, 2017
- Eisai Seeks HCC Indication for Lenvima in Japan
June 26, 2017
- Kyowa Kirin, LEO Pharma Tie Up for Gel Version of Dovobet Too
June 23, 2017
- Bioverativ Japan Files 4,000 IU Version for Hemophilia B Treatment Alprolix
June 23, 2017
- Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?
June 22, 2017
- EA Pharma to Discontinue Lentinan Sales amid Dwindling Demand
June 22, 2017
- Atsuo Takahashi Becomes Toa Eiyo President
June 22, 2017
- Takeda’s New Solid Dosage Form Production Facilities Completed in Germany
June 21, 2017
- Zeria to Terminate Development of Novel PPI
June 21, 2017
- Seikagaku Begins US PII Study of SI-613 for Knee Osteoarthritis
June 21, 2017
- Mitsubishi Tanabe Wins Fingolimod Patent Infringement Lawsuit in US
June 21, 2017
- Amgen Astellas Biopharma Gearing Up for 2020 Takeoff as Stand-Alone Subsidiary
June 20, 2017
- Takecab Most Heavily Promoted Drug for Hospital Doctors in April: Anterio
June 19, 2017
- Biogen Japan Upbeat on Tecfidera, Near-Approval Nusinersen, Sakigake Boost for Aducanumab
June 19, 2017
- Kaken, Numab Strike Deal for Multi-Specific Antibody in Inflammatory Disease
June 14, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…